Merck & Co., Inc. vs ZIM Integrated Shipping Services Ltd — how do they compare? Merck & Co., Inc. trades at $146.45 (market cap $351.28B), while ZIM Integrated Shipping Services Ltd trades at $30.13 (market cap $3.65B). The key difference: Merck & Co., Inc. is far larger — about 96.2× ZIM Integrated Shipping Services Ltd's market cap, and ZIM Integrated Shipping Services Ltd pays the higher dividend (20.16%). Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and ZIM Integrated Shipping Services Ltd for 27 Days on average.
| MRK | ZIM | |
|---|---|---|
Market Cap | $351.28B | $3.65B |
Volume | 7,969,665 | 1,068,475 |
Sector | Health | Industrials |
52-Week High | $156.43 | $30.51 |
52-Week Low | $82.49 | $12.44 |
Typical Hold Time | 98 Days | 27 Days |
Enterprise Value | $398.04B | $7.32B |
Dividend Yield | 2.39% | 20.16% |
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $144.96, up 1.52% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 72.97% gross margin and 28.07% net income margin for 2025, though its P/E ratio of 113.9 indicates high valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid competitive pressures.
The outlook is mixed: analyst consensus is bullish with a $158.78 price target, but technical indicators and a high P/E suggest near-term caution. Key risks include integration challenges from acquisitions and macroeconomic headwinds affecting pharmaceutical R&D investment. Revenue growth and pipeline execution remain critical for sustained upside.
ZIM Integrated Shipping Services trades at $30.31, up 1.07% with a bullish technical signal from moving averages. The stock shows mixed fundamentals with declining revenue from $6.9B in 2025 to $6.4B in 2026 and net income dropping from $479M to $139M, though Q2 2026 earnings beat expectations. Recent news highlights a potential $35 per share acquisition offer from Hapag-Lloyd pending Israeli government approval, creating significant uncertainty.
The investment outlook balances acquisition upside against operational challenges. While valuation metrics appear reasonable (P/E 26.31, P/S 0.57), declining profitability and the uncertain merger outcome present substantial risk. Analyst sentiment remains cautious with no buy ratings, reflecting concerns about the company's standalone prospects if the acquisition fails to materialize.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →ZIM is a global container liner shipping company that employs a 'global-niche' strategy, focusing on specific trade lanes where it holds a competitive advantage. Unlike larger, asset-heavy competitors, ZIM operates an agile, charter-intensive fleet, allowing it to rapidly adjust capacity to market demand while prioritizing digitalization and specialized cargo like refrigerated (reefer) goods.
Read more on ZIM →